Loading…
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $7M | $-221M | $-212M | $-207M | -33.5% | -23.2% | -27.5% |
| 2024 | $9M | $-151M | $-293M | $-164M | -161.7% | -35.5% | 174.3% |
| 2023 | $14M | $-28M | $-107M | $-8M | -89.1% | - | 189.5% |
| 2022 | $0M | $-36M | $-37M | $-29M | -221.6% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 14.02 | 9.04 | 6.94 |
| Operating Revenue | - | 0 | 14.02 | 9.04 | 6.94 |
| Operating Expense | - | 36.90 | 42.75 | 162.50 | 231.05 |
| Research And Development | - | 23.27 | 23.09 | 129.54 | 187.29 |
| Selling General And Administration | - | 13.63 | 19.66 | 32.96 | 43.77 |
| Total Expenses | - | 36.90 | 42.75 | 162.50 | 231.05 |
| Operating Income | - | -36.90 | -28.73 | -153.46 | -224.11 |
| Total Operating Income As Reported | - | -36.90 | -109.53 | -305.80 | -224.11 |
| EBITDA | - | -36.27 | -28 | -151.35 | -221.16 |
| Normalized EBITDA | - | -36.27 | 52.80 | 0.99 | -221.16 |
| EBIT | - | -36.90 | -28.73 | -153.46 | -224.11 |
| Interest Income | - | 0 | 2.72 | 12.84 | 11.72 |
| Interest Expense | 0.01 | - | - | - | - |
| Net Interest Income | - | 0 | 2.72 | 12.84 | 11.72 |
| Other Non Operating Income Expenses | 0.50 | - | - | - | - |
| Other Income Expense | 0.50 | - | -80.80 | -152.34 | - |
| Interest Income Non Operating | - | 0 | 2.72 | 12.84 | 11.72 |
| Interest Expense Non Operating | 0.01 | - | - | - | - |
| Net Non Operating Interest Income Expense | - | 0 | 2.72 | 12.84 | 11.72 |
| Pretax Income | - | -36.90 | -106.81 | -292.96 | -212.39 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -36.90 | -106.81 | -292.96 | -212.39 |
| Net Income From Continuing And Discontinued Operation | - | -36.90 | -106.81 | -292.96 | -212.39 |
| Net Income From Continuing Operation Net Minority Interest | - | -36.90 | -106.81 | -292.96 | -212.39 |
| Net Income | - | -36.90 | -106.81 | -292.96 | -212.39 |
| Net Income Common Stockholders | - | -37.52 | -106.81 | -292.96 | -212.39 |
| Net Income Including Noncontrolling Interests | - | -36.90 | -106.81 | -292.96 | -212.39 |
| Normalized Income | - | -36.90 | -26 | -140.62 | -212.39 |
| Diluted NI Availto Com Stockholders | - | -37.52 | -106.81 | -292.96 | -212.39 |
| Basic Average Shares | - | 12.13 | 19.84 | 58.64 | 87.35 |
| Diluted Average Shares | - | 12.13 | 19.84 | 58.64 | 87.35 |
| Reconciled Depreciation | - | 0.63 | 0.73 | 2.10 | 2.96 |
| Total Unusual Items | - | 0 | -80.80 | -152.34 | - |
| Total Unusual Items Excluding Goodwill | - | 0 | -80.80 | -152.34 | - |
| Special Income Charges | - | 0 | -80.80 | -152.34 | - |
| Other Special Charges | - | - | 80.80 | 152.34 | - |
| Restructuring And Mergern Acquisition | - | 0 | 80.80 | 152.34 | - |
| General And Administrative Expense | - | 13.63 | 19.66 | 32.96 | 43.77 |
| Other Gand A | - | 13.63 | 19.66 | 32.96 | 43.77 |
| Total Other Finance Cost | 0.01 | 0 | - | - | - |
| Otherunder Preferred Stock Dividend | 0 | 0.62 | 0 | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Immunome, Inc.this co. | IMNM | $2.2B | -10.49 | 3.51 | -33.5% | -7.14 |
| Celldex Therapeutics, Inc. | CLDX | $2.3B | -9.08 | 4.46 | -49.1% | -8.18 |
| Axogen, Inc. | AXGN | $2.3B | - | 17.49 | -12.2% | 4471.19 |
| Mineralys Therapeutics, Inc. | MLYS | $2.2B | -14.28 | 3.41 | -23.9% | - |
| Enliven Therapeutics, Inc. | ELVN | $2.2B | -20.85 |
| - |
| - |
| - |
| - |
| 4.70 |
| -22.6% |
| -17.28 |
| BioCryst Pharmaceuticals, Inc. | BCRX | $2.2B | 8.16 | -18.07 | -221.4% | 7.20 |
| Kodiak Sciences Inc. | KOD | $2.1B | - | 13.58 | -146.1% | - |
| Aurinia Pharmaceuticals Inc. | AUPH | $2.1B | 7.33 | 3.62 | 49.4% | 15.22 |
| Clover Health Investments, Corp. | CLOV | $2.1B | -24.56 | 6.81 | -27.7% | - |
| Peer Median | - | -11.68 | 4.58 | -25.8% | 7.20 | |